Flood of comments threatens to delay EMA data disclosure policy
This article was originally published in SRA
Executive Summary
The huge number of comments – more than 1,000 – received during the public consultation on the European Medicines Agency's proposed policy on clinical trial data disclosure means that finalising the policy may take longer than expected, and that it may well not come into effect on schedule next year1.